Skip to content
Open access

PredictRx: AI based decision support tool for molecular screening for breast cancer drug recommendation

Jul 2026 · Frontiers in Artificial Intelligence · Vol 9 · 0 citations · 54 references
Medicine

TL;DR

PredictRx shows how AI-driven predictive modeling which can speed up molecular screening and early-stage breast cancer medication discovery shows how AI-driven predictive modeling can speed up molecular screening and early-stage breast cancer medication discovery.

Abstract

Introduction Breast cancer remains one of the leading causes of cancer-related mortality rate worldwide, and the identification of effective drug combinations is an essential requirement in pharmaceutical research. The integration of Artificial Intelligence (AI) in processing large volumes of chemical and biological data combines molecular representation, predictive modeling and structured support within a single accessible tool, which accelerates early-stage candidate identification for breast cancer research while promoting reproducibility, transparency and user centered design. Aim The current research focuses on developing and designing “PredictRx” which is an artificial intelligence based driven decision support tool which tends to benefit healthcare practioners to analyze the combination of drug which can be utilized for breast cancer patients. Methodology PredictRx was developed using molecular descriptors, physicochemical properties, and drug interaction datasets collected from publicly available biomedical databases. The tool integrates in total six supervised and unsupervised learning techniques to examine the structural similarities between compounds and predict the potential drug interactions for breast cancer. Various machine learning techniques, including Random Forest, Support Vector Machine, Logistic Regression, K-Means Clustering, DBSCAN, and Agglomerative Clustering, to analyse structural similarities and predict potential drug interactions and synergy patterns. Model performance was evaluated using Classification matrix, Silhouette Score, Calinski-Harabasz Index, and Davies-Bouldin Index. The tool was deployed as a browser-accessible web application for real-time interaction and visualization. Result The results suggests that Random Forest has the highest predictive performance accuracy of 1, and Agglomerative clustering delivered strongest scores (Silhouette Score: 0.6946; Davies-Bouldin Index: 0.2457). The current tool was deployed as a browser accessible web tool with possibility of real time interaction and result visualization. PredictRx is a distinctive easy to use, and interpretable screening tool focused on drug compatibility and synergy analysis. EDA further identified molecular weight, lipophilicity, and structural similarity as important contributors to drug compatibility prediction. Conclusion PredictRx shows how AI-driven predictive modeling which can speed up molecular screening and early-stage breast cancer medication discovery. The technology facilitates the effective identification of appropriate drug combinations and offers a scalable foundation for upcoming AI-assisted pharmaceutical research by combining clustering, classification, molecular representation, and visualization into a single interpretable platform.

Read PDF

Similar papers

Conference Jul 2026

Explainable Multi-Omic Machine Learning Framework for Predicting Drug Response in Breast Cancer

Accurate prediction of drug sensitivity in cancer cell lines is vital for precision oncology and patient-specific therapies. However, many computational approaches fail to integrate multi-modal biological and chemical features and often struggle with high-dimensional, imbalanced pharmacogenomic data, limiting predictiv...

D. Kumari, Aiman, Sakshi Singh et al. · 0 citations
Review Open access Jul 2026

Advanced Artificial Intelligence and data science in bioinformatics-driven drug discovery for cancer: Pathways toward shorter and less toxic treatment

Recent literature on the application of artificial intelligence (AI) and data science within bioinformatics-driven cancer drug discovery is synthesized, examining how these tools are reshaping target identification, molecular design, biomarker discovery, and treatment personalization.

Yejide Eniola Dabiri · 0 citations
Open access Jul 2026

Machine Learning-Based Multi-Cancer Diagnostic System for Early Detection and Accurate Classification Across Diverse Cancer Types

The proposed framework incorporates data preprocessing, feature selection, and advanced classification algorithms to enhance diagnostic accuracy and facilitate timely clinical decision-making to emphasize the potential of artificial intelligence in advancing precision oncology and improving healthcare outcomes.

Sakshi Singh, Saurav Kumar, Yusuf Perwej et al. · 0 citations
Review Aug 2026

Advancing cancer drug discovery through the integration of machine learning and high-throughput screening.

This review highlights the synergy between AI and HTS, emphasizing DL techniques such as convolutional neural networks for bioactivity prediction, recurrent neural networks for de novo design, and reinforcement learning for property optimization.

Kamil Herbetko, Katarzyna Herbetko, Magdalena Mikołajek et al. · 1 citation
Conference Aug 2026

Predictive Artificial Intelligence Approaches for Accurate Drug Classification in Pharmaceutical Industry

Drug classification plays a critical role in medicine as it aids in selecting the best medicines for an individual’s needs based on their individual characteristics and history. Computational methods are increasingly used in drug discovery to build structure-activity models for large chemical databases. This study intr...

Nazia F Shaik · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.